Daclatasvir Dihydrochloride
Deskripsyon
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) se yon pisan ak oralman aktif.HCV NS5A pwoteyininhibiteur akEC50s ranje 9-146 pM pouplizyè jenotip replikon HCV.Daclatasvir dihydrochloride se tou yonòganik anyon transpòte polipèptid 1B (OATP1B)epiOATP1B3inhibiteur akIC50s nan 1.5 µM ak 3.27 µM, respektivman.
IC50& Sib
EC50: 50 pM (HCV replicon jenotip 1a), 9 pM (HCV replicon jenotip 1b), 71 pM (HCV replicon jenotip 2a), 146 pM (HCV replicon jenotip 3a), 12 pM (HCV replicon jenotip 4a) ak HCV replicon jenotip 5a)[1]
Kd: 8 nM (NS5A33-202) ak 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) ak 3.27 µM (OATP1B3)[3]
In vitro
Daclatasvir (BMS-790052) demontre aktivite inhibitor ki pisan nan direksyon pou tout jenotip yo teste, ak EC.50valè ki sòti nan 9 pM a 146 pM.Daclatasvir inibit HCV replicon jenotip 1a, 1b, 2a, 3a, 4a ak 5a ak EC50valè 50 pM, 9 pM, 71 pM, 146 pM, 12 pM ak 33 pM, respektivman.Daclatasvir se yon inibitè ki pisan nan viris enfektye JFH-1 jenotip 2a ki repwodui nan kilti selilè (EC).50= 28 pM)[1].Daclatasvir (BMS-790052) mare byen sere nan NS5A33-202 ak NS5A26-202 ak K.ds nan 8 nM ak 210 nM, respektivman[2].
Depo
Poud | -20°C | 3 zan |
4°C | 2 zan | |
Nan sòlvan | -80°C | 6 mwa |
-20°C | 1 mwa |
Esè klinik
Nimewo NCT | Sponsor | Kondisyon | Dat Kòmanse | Faz |
NCT03369327 | Tehran University of Medical Sciences|RojanPharma Pharmaceutical Company | Enfeksyon Viris Epatit C, Repons a Terapi |Viris Iminodefisyans Imèn | 1ye janvye 2017 | Faz 3 |
NCT03485846 | R-Pharm|Almedis | Epatit C kwonik jenotip 1b | 27 novanm 2017 | Faz 2 |
NCT01016912 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2009 | Faz 2 |
NCT01629732 | Bristol-Myers Squibb | Viris Epatit C | Mas 2013 | Faz 2 |
NCT01497834 | Bristol-Myers Squibb | Epatit C | Janvye 2012 | Faz 3 |
NCT01973049 | Bristol-Myers Squibb | Epatit C | Desanm 2013 | Faz 3 |
NCT00663208 | Bristol-Myers Squibb | Epatit C kwonik | Me 2008 | Faz 2 |
NCT02576314 | Sant rechèch limanite ak sante|Beijing 302 Lopital | Enfeksyon kwonik epatit C | Me 2015 | Faz 3 |
NCT02756936 | Genuine Research Center, peyi Lejip|Zeta Pharmaceutical Industries | An sante | Fevriye 2016 | Faz 1 |
NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Cairo University | Epatit C, Kwonik|Kansòm epatoselilè | Mas 2016 | Faz 3 |
NCT03706898 | Viriom | VIH-1-enfeksyon|Defisyans Epatik | 1ye oktòb 2018 | Faz 1 |
NCT02319031 | Bristol-Myers Squibb | Epatit C | Fevriye 2015 | Faz 3 |
NCT02124044 | National Institutes of Health Clinical Center (CC)|Enstiti Nasyonal pou Alèji ak Maladi Enfektye (NIAID)|Bristol-Myers Squibb | VIH-HCV | Fevriye 2014 | Faz 2 |
NCT02551861 | Bristol-Myers Squibb | Epatit C | Desanm 2015 | Faz 2 |
NCT00859053 | Bristol-Myers Squibb | Ensifizans epatik | Mas 2009 | Faz 1 |
NCT01257204 | Bristol-Myers Squibb | Viris Epatit C | Desanm 2010 | Faz 2 |
NCT03063879 | Tehran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|University of Medical Sciences Hamadan | Epatit C, Kwonik | Ensifizans Renal Kwonik | 1ye avril 2017 | Faz 4 |
NCT01017575 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2009 | Faz 2 |
NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Epatit C kwonik | Septanm 2016 |
|
NCT04070235 | Nanjing Sanhome famasetik, co, Ltd. | Epatit C, kwonik | 29 mas 2019 | Faz 2| Faz 3 |
NCT03487848 | Bristol-Myers Squibb | Epatit C|Epatit kwonik | 18 me 2018 | Faz 2 |
NCT00904059 | Bristol-Myers Squibb | Epatit C | Me 2009 | Faz 1 |
NCT02107365 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Epatit C Viris Jenotip 4 Enfeksyon | Novanm 2013 | Faz 2 |
NCT02397395 | Janssen R&D Iland | Enfimite Renal|Maladi Renal Etap Fen | Me 2015 | Faz 2 |
NCT03169348 | Inivèsite Assiut | Epatit C | 1ye novanm 2017 | Pa aplikab |
NCT02323594 | Bristol-Myers Squibb | Enfeksyon epatit C | Desanm 2014 | Faz 1 |
NCT03537196 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS) | Epatit C|Itilize dwòg|Epatit C viral | 13 novanm 2018 | Faz 4 |
NCT02103569 | Bristol-Myers Squibb | Epatit C | Avril 2014 | Faz 1 |
NCT02772744 | Zagazig University|Kairo University | Epatit C | 1ye novanm 2017 |
|
NCT01718158 | Bristol-Myers Squibb | Epatit C | Janvye 2013 | Faz 3 |
NCT02496078 | Bristol-Myers Squibb | Epatit C | Out 2015 | Faz 3 |
NCT01425970 | Bristol-Myers Squibb | Epatit C | Me 2012 | Faz 2 |
NCT01471574 | Bristol-Myers Squibb | Epatit C, jenotip 1 | Desanm 2011 | Faz 3 |
NCT01573351 | Bristol-Myers Squibb | Viris Epatit C | Me 2012 | Faz 3 |
NCT01938625 | Janssen R&D Iland | Epatit C, kwonik | 12 desanm 2013 | Faz 2 |
NCT01492426 | Bristol-Myers Squibb | Epatit C | Janvye 2012 | Faz 3 |
NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center for AIDS Research and Education | Epatit C, kwonik | 2 fevriye 2018 | Faz 2| Faz 3 |
NCT03163849 | Inivèsite Assiut | Epatit kwonik c | 1ye septanm 2019 | Faz 3 |
NCT01581203 | Bristol-Myers Squibb | Viris Epatit C | Me 2012 | Faz 3 |
NCT01492504 | Bristol-Myers Squibb | Epatit C | 7 fevriye 2012 |
|
NCT03686722 | Mohamed Raslan|Ain Shams University|Drog Research Center, Cairo, Egypt | Dyabèt Melito, Kalite 2|Epatit C|Entèaksyon Medikaman | 9 septanm 2017 | Faz 1 |
NCT02262728 | Janssen Research & Development, LLC | Epatit C, kwonik | 30 septanm 2014 | Faz 2 |
NCT02349048 | Janssen Research & Development, LLC | Viris Epatit C | Janvye 2015 | Faz 2 |
NCT03882307 | Inivèsite Assiut | Epatit C, kwonik | Me 2020 | Faz bonè 1 |
NCT02758509 | Parc de Salut Mar | Epatit C kwonik | Siwoz | 1ye janvye 2010 |
|
NCT01795911 | Bristol-Myers Squibb | Epatit C | Mas 2013 | Faz 2 |
NCT03549832 | Assiut University|Sohag University|South Valley University | Koinfeksyon HCV | 1ye janvye 2018 | Pa aplikab |
NCT02161939 | Bristol-Myers Squibb | Epatit C kwonik |
| |
NCT01309932 | Bristol-Myers Squibb | Epatit C | Mas 2011 | Faz 2 |
NCT01995266 | Bristol-Myers Squibb | Epatit C | 28 fevriye 2014 | Faz 3 |
NCT02640157 | AbbVie | Epatit C Kwonik|Viris Epatit C|Jenotip 3 Viris Epatit C | Desanm 2015 | Faz 3 |
NCT02032875 | Bristol-Myers Squibb | Epatit C | Mas 2014 | Faz 3 |
NCT02624063 | Inivèsite Federal São Paulo | Epatit C, kwonik | Desanm 2015 | Faz 4 |
NCT00546715 | Bristol-Myers Squibb | Epatit C kwonik | Novanm 2007 | Faz 1 | Faz 2 |
NCT01718145 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Novanm 2012 | Faz 3 |
NCT01616524 | Bristol-Myers Squibb | Viris Epatit C (HCV) | Jiyè 2012 | Faz 3 |
NCT02032901 | Bristol-Myers Squibb | Epatit C | Janvye 2014 | Faz 3 |
NCT03540212 | Inivèsite Ain Shams | Enfeksyon kwonik HCV | 10 desanm 2017 | Faz 2| Faz 3 |
NCT02097966 | Bristol-Myers Squibb | Epatit C kwonik |
| |
NCT02596880 | Teheran University of Medical Sciences | Epatit C | Siwoz | Septanm 2015 | Faz 3 |
NCT04019717 | Atea Pharmaceuticals, Inc. | Epatit C|Epatit C, Kwonik|Epatit C kwonik|Enfeksyon Viris Epatit C|Enfeksyon HCV | 20 jen 2019 | Faz 2 |
NCT02992457 | Tanta Inivèsite | Epatit C | Janvye 2015 | Faz 4 |
NCT03547895 | Inivèsite Zagazig | Siwoz dekonpanse | 1ye jen 2015 | Pa aplikab |
NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Epatit C | Novanm 2016 | Faz 3 |
NCT01051414 | Bristol-Myers Squibb | Enfeksyon epatit C | Avril 2010 | Faz 2 |
NCT02309450 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Epatit C Viris Jenotip 4 Enfeksyon | Desanm 2014 | Faz 2 |
NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Viris Epatit C | Jiyè 2012 | Faz 2 |
NCT03186313 | Lopital fwa moun peyi Lejip|Wadi El Nil Hospital | Epatit C | Septanm 2016 | Faz 3 |
NCT03063723 | Twazyèm Lopital Afilye, Inivèsite Sun Yat-Sen | Epatit C kwonik (Trouble) | 1ye janvye 2016 |
|
NCT00983957 | Bristol-Myers Squibb | Epatit C kwonik | Oktòb 2009 | Faz 1 |
NCT01725542 | Enstiti nasyonal franse pou sante ak rechèch medikal-Ajans nasyonal franse pou rechèch sou SIDA ak epatit viral (Inserm-ANRS)|Bristol-Myers Squibb | Ko-enfeksyon HCV-VIH | Desanm 2012 | Faz 2 |
NCT02282709 | Fondasyon pou rechèch nan fwa | Epatit C kwonik | Fevriye 2014 | Faz 3 |
NCT02032888 | Bristol-Myers Squibb | Epatit C | Fevriye 2014 | Faz 3 |
NCT03247296 | Inivèsite MTI | Epatit C | 28 fevriye 2017 |
|
NCT01389323 | Bristol-Myers Squibb | Epatit C | Septanm 2011 | Faz 3 |
NCT02556086 | Bristol-Myers Squibb | Epatit C | Desanm 2015 | Faz 2 |
NCT01741545 | Bristol-Myers Squibb | Viris Epatit C | 31 mas 2013 | Faz 3 |
NCT01866930 | Bristol-Myers Squibb | Enfeksyon kwonik epatit C | 11 jiyè 2013 | Faz 3 |
NCT02268864 | Janssen-Cilag International NV | Epatit C, kwonik | Janvye 2015 | Faz 2 |
NCT01797848 | Bristol-Myers Squibb | Epatit C | jen 2014 | Faz 3 |
NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | Epatit C | jen 2017 |
|
NCT02159352 | Bristol-Myers Squibb | Epatit C | jen 2014 | Faz 1 |
NCT01125189 | Bristol-Myers Squibb | Viris Epatit C | Jiyè 2010 | Faz 2 |
NCT03748745 | Nanjing Sanhome famasetik, co, Ltd. | Entèaksyon Dwòg | 19 novanm 2018 | Faz 1 |
NCT01012895 | Bristol-Myers Squibb | Epatit C kwonik | Desanm 2009 | Faz 2 |
NCT02565888 | Inivèsite Radboud | Epatit C|VIH | Novanm 2015 | Faz 1 |
NCT02555943 | Sant rechèch limanite ak sante|Beijing 302 Hospital|Nanfang Hospital nan Southern Medical University | Enfeksyon Epatit C kwonik|Koenfeksyon HBV|Reaktivasyon Epatit B | Fevriye 2015 | Faz 2| Faz 3 |
NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center | Epatit C | Siwoz | Janvye 2015 | Faz 4 |
NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent´s Hospital, Kore di|Konkuk University Hospital|Cheongju St. Mary´s Hospital, Cheongju , Kore|Lopital Severance|Kore di Inivèsite Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Epatit C | Fevriye 2016 | Faz 4 |
NCT02104843 | Bristol-Myers Squibb | Epatit C | Avril 2014 | Faz 1 |
NCT01428063 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Septanm 2011 | Faz 2 |
NCT02123654 | Bristol-Myers Squibb | Enfeksyon Viris Epatit C | Avril 2014 | Faz 3 |
NCT02565862 | Inivèsite Radboud | Epatit C|Dyabèt melitu|Rezistans ensilin | Janvye 2016 | Faz 1 |
NCT04211844 | Inivèsite Ain Shams | Epatit C kwonik | 1ye oktòb 2019 |
|
NCT00874770 | Bristol-Myers Squibb | Enfeksyon epatit C | jen 2009 | Faz 2 |
NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Ensifizans ren, Kwonik|Epatit C | 15 mas 2019 | Faz 3 |
NCT01448044 | Bristol-Myers Squibb | Epatit C | Desanm 2011 | Faz 3 |
NCT01359644 | Bristol-Myers Squibb|Pharmasset | Epatit C kwonik | jen 2011 | Faz 2 |
NCT01842451 | Vertex Pharmaceuticals Incorporated | Epatit C kwonik|CHC|HCV|Epatit C | jen 2013 | Faz 2 |
NCT02762448 | Lopital Minisipal Tainan | Epatit c | Jiyè 2016 |
|
NCT02473211 | Sant rechèch limanite ak sante|Beijing 302 Lopital | Enfeksyon kwonik epatit C | Janvye 2015 | Faz 2| Faz 3 |
NCT01455090 | Bristol-Myers Squibb | Epatit C kwonik | 30 novanm 2011 | Faz 2 |
NCT03490097 | Inivèsite Ain Shams | Epatit kwonik c|Sendwòm metabolik | 1ye desanm 2017 | Faz 2| Faz 3 |
NCT01170962 | Bristol-Myers Squibb | Viris Epatit C | Out 2010 | Faz 2 |
NCT02333292 | Hospital Universitario Valme|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias| Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Lopital Jeneral Universitario de Castellón|Lopital Parc Taulí, Sabadell | Enfeksyon kwonik epatit C | Desanm 2014 |
|
NCT03200184 | Teheran University of Medical Sciences | Epatit C | 1ye septanm 2016 | Faz 4 |
NCT03188276 | Twazyèm Lopital Afilye, Inivèsite Sun Yat-Sen | Epatit C kwonik | 1ye fevriye 2016 | Faz bonè 1 |
NCT01830205 | Bristol-Myers Squibb | Epatit C | Septanm 2012 | Faz 1 |
![2018 GMP-2](http://www.cz-pharma.com/uploads/beaa7119.jpg)
![原料药GMP证书201811(captopril ,thalidomide etc)](http://www.cz-pharma.com/uploads/15b802ef.jpg)
![GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co](http://www.cz-pharma.com/uploads/40ac545a.jpg)
![FDA-EIR-Letter-201901](http://www.cz-pharma.com/uploads/FDA-EIR-Letter-201901.jpg)
![Quality management1](http://www.cz-pharma.com/uploads/Quality-management1.png)
Pwopozisyon18Pwojè Evalyasyon Konsistans Kalite ki te apwouve4, epi6pwojè yo anba apwobasyon.
![Quality management2](http://www.cz-pharma.com/uploads/Quality-management2.png)
Sistèm avanse jesyon kalite entènasyonal te mete yon fondasyon solid pou lavant yo.
![Quality management3](http://www.cz-pharma.com/uploads/Quality-management3.png)
Sipèvizyon kalite kouri atravè tout sik lavi pwodwi a pou asire bon jan kalite a ak efè ki ka geri ou.
![Quality management4](http://www.cz-pharma.com/uploads/Quality-management4.png)
Ekip Pwofesyonèl Afè Regilasyon sipòte demann kalite yo pandan aplikasyon an ak enskripsyon an.
![cpf5](http://www.cz-pharma.com/uploads/cpf5.png)
![cpf6](http://www.cz-pharma.com/uploads/cpf6.png)
Kore di Countec boutèy anbalaj liy
![cpf7](http://www.cz-pharma.com/uploads/cpf7.png)
![cpf8](http://www.cz-pharma.com/uploads/cpf8.png)
Taiwan CVC boutèy anbalaj liy
![cpf9](http://www.cz-pharma.com/uploads/cpf9.png)
![cpf10](http://www.cz-pharma.com/uploads/cpf10.png)
Itali CAM Board Packaging Liy
![cpf11](http://www.cz-pharma.com/uploads/cpf11.png)
Alman Fette Compacting machin
![cpf12](http://www.cz-pharma.com/uploads/cpf12.png)
Japon Viswill tablèt detektè
![cpf14-1](http://www.cz-pharma.com/uploads/cpf14-1.png)
Sal kontwòl DCS
![International cooperation](http://www.cz-pharma.com/uploads/International-cooperation.jpg)
![Domestic cooperation](http://www.cz-pharma.com/uploads/Domestic-cooperation.jpg)